CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Akili, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Akili, Inc.
71 Commercial Street, Mailbox 312
Phone: (617) 456-0597p:617 456-0597 BOSTON, MA  02109  United States Ticker: AKLIAKLI
This company was Merged or Acquired on 7/2/2024.
This company ceased filing statements with the SEC on 7/12/2024.
The Company was acquired by Virtual Therapeutics Corporation, a subsidiary of UnitedHealth Group Inc
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Company’s approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202412/31/2023YesYes---

Industries
SIC Code Description
3845 Electromedical and electrotherapeutic apparatus
6770 Blank checks
7371 Computer programming services
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Co-Founder W. E.Martucci 42 10/5/2023 8/1/2022
President, Chief Executive Officer, Director MatthewFranklin 50 10/5/2023 8/1/2022
Co-Founder, Director AdamGazzaley 55 8/1/2022 8/1/2022
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Akili Inc
Akili Interactive Labs, Inc.
AKLI

General Information
Number of Employees: 36 (As of 3/31/2024)
Outstanding Shares: 78,726,725 (As of 5/23/2024)
Shareholders: 38
Stock Exchange: NASD
Federal Tax Id: 981586159
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024